Critical evaluation of the efficacy and tolerability of azilsartan.

Article Details

Citation

De Caterina AR, Harper AR, Cuculi F

Critical evaluation of the efficacy and tolerability of azilsartan.

Vasc Health Risk Manag. 2012;8:299-305. doi: 10.2147/VHRM.S22589. Epub 2012 May 14.

PubMed ID
22661897 [ View in PubMed
]
Abstract

Appropriate control of blood pressure (BP) in hypertensive patients still represents the major therapeutic goal in the treatment of hypertension. Despite the growing attention and wide range of antihypertensive agents available in the clinical scenario, the target of BP below the advised thresholds of 140/90 mmHg is, unfortunately, often unreached. For this reason, the search for new antihypertensive agents is still ongoing. Azilsartan medoxomil, a new angiotensin receptor blocker that has been recently introduced in the clinical arena, represents the eighth angiotensin receptor blocker currently available for BP control. The aim of this paper is to describe the efficacy and safety profile of this new compound, reviewing available data obtained from both pre-clinical and clinical studies.

DrugBank Data that Cites this Article

Drugs
Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
Azilsartan medoxomilCytochrome P450 2B6ProteinHumans
No
Substrate
Details
Azilsartan medoxomilCytochrome P450 2C8ProteinHumans
No
Substrate
Details
Drug Transporters
DrugTransporterKindOrganismPharmacological ActionActions
Azilsartan medoxomilP-glycoprotein 1ProteinHumans
No
Inhibitor
Details
Drug Reactions
Reaction
Azilsartan medoxomil
DB08822
    Details
    Drug Interactions
    DrugsInteraction
    Azilsartan medoxomil
    Fluconazole
    The metabolism of Azilsartan medoxomil can be decreased when combined with Fluconazole.